Medipostco Launches Stem Cell Cell Bank Service Based on Domestically Produced Culture Plates
Predicted impact: Low
Stem cell bank service launch repeats the recent AOF stem cell bank announcement
Medipostco메디포스트
078160 · KOSDAQ · ₩078160 · 메디포스트
₩8,490▲ ₩200 (2.41%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −43.96%
- Market cap
- ₩333B
- Enterprise value
- ₩298B
- P/E
- —
- P/B
- 1.2×
- Dividend yield
- 0.0%
- ROE
- −8.5%
- Net margin
- −30.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−70.8% from the high
₩7,250Today: ₩8,410 – ₩8,630₩29,100
Returns
- 1W−5.4%
- 1M−5.4%
- 3M+5.2%
- 6M−68.7%
- YTD−53.3%
- 1Y−44.0%
- Volume today
- 35,015
- 0.7× the 20-day average
- Traded today
- ₩298M
- Listed shares
- 39,204,603
- EPS (12 months)
- −₩589
- Earnings yield −6.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headlines describe a new service launch and business expansion. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-5.4% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Medipostco stock overview
Medipostco (메디포스트, KRX: 078160) is listed on KOSDAQ, in the Biotech & Pharma sector. The company operates a cord blood bank under the Celltree brand, which holds the top domestic market share and offers family cord blood storage. Its shares closed at ₩8,490 on Oct 27, 2026, up 2.41% on the day, giving it a market value of ₩333B.
Key facts
- Market cap
- ₩333B
- Sector
- Biotech & Pharma
- Latest price change
- +2.41%
- As of
- Oct 27, 2026
- Main business
- The company operates a cord blood bank under the Celltree brand, which holds the top domestic market share and offers family cord blood storage.
Quick answers about Medipostco
- What does Medipostco do?
- The company operates a cord blood bank under the Celltree brand, which holds the top domestic market share and offers family cord blood storage. It also develops and sells the knee osteoarthritis stem cell therapy Cartistem, provides CDMO services, and sells the Movita-brand health functional foods, with customers served through hospitals, online channels and direct sales. Its operations are based in Seongnam, Gyeonggi-do, and include a cell therapy GMP facility in Guro-gu, Seoul.
- What is the market cap of Medipostco?
- The market capitalisation of Medipostco was ₩333B at the close on Oct 27, 2026.
- Who are the largest shareholders of Medipostco?
- According to the latest official filings, the largest reported holders are Sky Medical (53.77%, as of Jan 13, 2026); Marble 2022 Holdings (50.71%, as of Jan 20, 2026); NH Woori New Deal Growth Alpha No. 1 Private Equity Fund (7.24%, as of Jan 7, 2026).
- When is the next earnings report from Medipostco?
- Korean companies rarely announce results dates in advance. Based on when Medipostco filed the same report in past years, its next preliminary results is expected around Oct 25, 2026.
- Does the National Pension Service own Medipostco?
- Yes. The National Pension Service held 1.55% of Medipostco shares as of Dec 31, 2025.
Company profile
The company operates a cord blood bank under the Celltree brand, which holds the top domestic market share and offers family cord blood storage. It also develops and sells the knee osteoarthritis stem cell therapy Cartistem, provides CDMO services, and sells the Movita-brand health functional foods, with customers served through hospitals, online channels and direct sales. Its operations are based in Seongnam, Gyeonggi-do, and include a cell therapy GMP facility in Guro-gu, Seoul.
Written by AI from the company's latest annual report.
- Korean name
- 메디포스트
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 오원일
- Founded
- Jun 2000
- Listed
- Jul 2005
- Listed shares
- 39,204,603
- Fiscal year ends
- Month 12
- Website
- www.medi-post.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Medipostco launches service to build domestic AOF stem cell bank, expanding CDMO business
Predicted impact: Low
Recent filings
See all- Reference Document for Proxy Solicitation of Voting RightsOct 14, 2026
- Notice of shareholders' meetingOct 14, 2026
- Determination of Shareholder Register Closure Period or Record DateSep 15, 2026
- Shareholders' meeting calledSep 15, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Medipostco / 메디포스트 / 078160 / KRX:078160
Source: KRX statistical information